Novavax Aims for Billions Covid Vaccine Doses Could Be Available by End of 2021

Some of the world’s largest biopharma companies are working to deliver safe and effective COVID-19 vaccines, but at the same time, a much smaller biotech has laid out its own big ambitions in the field. Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives say. On a conference call Monday, chief medical officer Filip Dubovsky said the Gaithersburg, MD-based biotech expects to be able to make "well over a couple billion units" each year, starting in 2021. That would easily outpace U.S. demand, which Dubovsky estimated will come in at 500 million to 600 million doses annually.